Latest News and Press Releases

PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.

PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio

PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan

PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.

PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1

PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant

PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update

PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program

PharmAla completes private placement and concurrent debt settlement with Advisor.

PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024